p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts.

"Declarations Conflict of interestThe authors report no relevant conflicts of interest for the submitted work. David P. Lane has received support from Merck, Ipsen and Asian. David P. Lane is involved in a collaborative project with Merck on macrocyclic peptides and have a patent issued (WO2014055039A1) on Peptides and Methods for Treating Cancer. Marika Nestor is a co-founder and shareholder of Akiram Therapeutics. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Conflict of interest The authors report no relevant conflicts of interest for the submitted work. David P. Lane has received support from Merck, Ipsen and Asian. David P. Lane is involved in a collaborative project with Merck on macrocyclic peptides and have a patent issued (WO2014055039A1) on Peptides and Methods for Treating Cancer. Marika Nestor is a co-founder and shareholder of Akiram Therapeutics. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."

"Funding Open access funding provided by Uppsala University. The study was supported by The Swedish Childhood Cancer Fund (PR2020-0023, TJ2021-0072) and Stiftelsen Ulf Lundahls minnesfond, the Swedish Research Council (2020-01377) and the Swedish Cancer Society (CAN 2018/494, CAN 20 0191)."